Biotech Values

[DewDiligence]

…even if IMCR is successful it will most likely need to be used w other drugs (like those being developed by ENTA) to directly target the [HBV] viral life cycle.

Moreover, IMCR’s drug for HBV can’t be made into an oral agent.